Gender characterization in a large series of Brazilian patients with spondyloarthritis

Carregando...
Imagem de Miniatura
Citações na Scopus
59
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER LONDON LTD
Autores
CARVALHO, Hellen M. S. de
BORTOLUZZO, Adriana B.
SILVA, Jose Antonio Braga da
XIMENES, Antonio Carlos
BERTOLO, Manoel B.
RIBEIRO, Sandra L. E.
KEISERMAN, Mauro
MENIN, Rita
SKARE, Thelma L.
Citação
CLINICAL RHEUMATOLOGY, v.31, n.4, p.687-695, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
An increasing number of women have been diagnosed with spondyloarthritis (SpA) in recent decades. While a few studies have analyzed gender as a prognostic factor of the disease, no studies have addressed this matter with a large number of patients in South America, which is a peculiar region due to its genetic heterogeneity. The aim of the present study was to analyze the influence of gender on disease patterns in a large cohort of Brazilian patients with SpA. A prospective study was carried out involving 1,505 patients [1,090 males (72.4%) and 415 females (27.6%)] classified as SpA according to the European Spondyloarthropaties Study Group criteria who attended at 29 reference centers for rheumatology in Brazil. Clinical and demographic variables were recorded and the following disease indices were administered: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Radiologic Index (BASRI), Maastricht Ankylosing Spondylitis Enthesitis Score (MASES), and Ankylosing Spondylitis Quality of Life (ASQoL). Ankylosing spondylitis (AS) was the most frequent disease in the group (65.4%), followed by psoriatic arthritis (18.4%), undifferentiated SpA (6.7%), reactive arthritis (3.3%), arthritis associated to inflammatory bowel disease (3.2%), and juvenile SpA (2.9%). The male-to-female ratio was 2.6:1 for the whole group and 3.6:1 for AS. The females were older (p<0.001) and reported shorter disease duration (p=0.002) than the male patients. The female gender was positively associated to peripheral SpA (p<0.001), upper limb arthritis (p<0.001), dactylitis (p=0.011), psoriasis (p<0.001), nail involvement (p<0.001), and family history of SpA (p=0.045) and negatively associated to pure axial involvement (p< 0.001), lumbar inflammatory pain (p=0.042), radiographic sacroiliitis (p<0.001), and positive HLA-B27 (p=0.001). The number of painful (p<0.001) and swollen (p=0.006) joints was significantly higher in the female gender, who also achieved higher BASDAI (p<0.001), BASFI (p=0.073, trend), MASES (p=0.019), ASQoL (p=0.014), and patient's global assessment (p=0.003) scores, whereas the use of nonsteroidal anti-inflammatory drugs (p<0.001) and biological agents (p=0.003) was less frequent in the female gender. Moreover, BASRI values were significantly lower in females (p<0.001). The female gender comprised one third of SpA patients in this large cohort and exhibited more significant peripheral involvement and less functional disability, despite higher values in disease indices.
Palavras-chave
Gender, Prognosis, Spondyloarthritis
Referências
  1. Aloush A, 2007, RHEUMATOL INT, V27, P865
  2. Arends S, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3369
  3. Azevedo Valderilio Feijó, 2010, Rev Bras Reumatol, V50, P646, DOI 10.1590/S0482-50042010000600005
  4. Barlow J H, 1993, Arthritis Care Res, V6, P45, DOI 10.1002/art.1790060109
  5. Bonfiglioli R, 2008, CLIN RHEUMATOL, V27, P709, DOI 10.1007/s10067-007-0770-3
  6. CALIN A, 1994, J RHEUMATOL, V21, P2281
  7. CARBONE LD, 1992, ARTHRITIS RHEUM, V35, P1476, DOI 10.1002/art.1780351211
  8. Cusmanich KG, 2006, THESIS U SAO PAULO
  9. Dernis E, 2009, ANN RHEUM DIS, V68, P502, DOI 10.1136/ard.2008.089599
  10. DOUGADOS M, 1991, ARTHRITIS RHEUM, V34, P1218, DOI 10.1002/art.1780341003
  11. Doward LC, 2003, ANN RHEUM DIS, V62, P20, DOI 10.1136/ard.62.1.20
  12. GARRETT S, 1994, J RHEUMATOL, V21, P2286
  13. GLADMAN DD, 1992, CLIN INVEST MED, V15, P371
  14. Glintborg B, 2010, ANN RHEUM DIS, V69, P202
  15. GRAN JT, 1990, SEMIN ARTHRITIS RHEU, V19, P303, DOI 10.1016/0049-0172(90)90053-I
  16. GRAN JT, 1985, J RHEUMATOL, V12, P126
  17. Heuft-Dorenbosch L., 2003, Annals of the Rheumatic Diseases, V62, P127, DOI 10.1136/ard.62.2.127
  18. JONES SD, 1995, J RHEUMATOL, V22, P1609
  19. KENNEDY LG, 1993, J RHEUMATOL, V20, P1900
  20. Kingsley G, 1996, ANN RHEUM DIS, V55, P564, DOI 10.1136/ard.55.8.564
  21. Lanna CCD, 2008, CLIN RHEUMATOL, V27, P503, DOI 10.1007/s10067-007-0797-5
  22. Lee W, 2008, ARTHRIT RHEUM-ARTHR, V59, P449, DOI 10.1002/art.23321
  23. Lee W, 2007, ANN RHEUM DIS, V66, P633, DOI 10.1136/ard.2006.060293
  24. Lord PAC, 2010, RHEUMATOLOGY, V49, P563, DOI 10.1093/rheumatology/kep422
  25. MOLL J M H, 1973, Seminars in Arthritis and Rheumatism, V3, P55, DOI 10.1016/0049-0172(73)90035-8
  26. Queiro R, 2001, RHEUMATOL INT, V21, P66
  27. Roussou E, 2011, CLIN RHEUMATOL, V30, P121, DOI 10.1007/s10067-010-1581-5
  28. Rudwaleit M, 2011, ANN RHEUM DIS, V70, P25, DOI 10.1136/ard.2010.133645
  29. Sampaio-Barros, 2008, REUMATOL CLIN S4, V4, pS30
  30. Sampaio-Barros PD, 2008, RHEUMATOL INT, V28, P483, DOI 10.1007/s00296-007-0441-3
  31. Sampaio-Barros PD, 2010, J RHEUMATOL, V37, P1195, DOI 10.3899/jrheum.090625
  32. Sampaio-Barros PD, 2001, J RHEUMATOL, V28, P560
  33. Sieper J, 2009, ANN RHEUM DIS S, V68, pi1
  34. Slobodin G, 2011, CLIN RHEUMATOL, V30, P1075, DOI 10.1007/s10067-011-1719-0
  35. VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361
  36. Vazquez-Mellado J, 2008, REUMATOL CLIN S4, V4, pS17
  37. Wallenius M, 2009, ANN RHEUM DIS, V68, P685, DOI 10.1136/ard.2008.092049
  38. Wanders AJB, 2004, ARTHRITIS RHEUM, V50, P2622, DOI 10.1002/art.20446
  39. Weisman M, 2010, J RHEUMATOL, V37, P2617, DOI 10.3899/jrheum.100890
  40. WILL R, 1990, J RHEUMATOL, V17, P1649